Please use this identifier to cite or link to this item:
http://doi.org/10.25358/openscience-5804
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Almstedt, Katrin | - |
dc.contributor.author | Mendoza, S. | - |
dc.contributor.author | Otto, M. | - |
dc.contributor.author | Battista, M. J. | - |
dc.contributor.author | Steetskamp, Joscha | - |
dc.contributor.author | Heimes, Anne-Sophie | - |
dc.contributor.author | Krajnak, Slavomir | - |
dc.contributor.author | Poplawski, A. | - |
dc.contributor.author | Gerhold-Ay, A. | - |
dc.contributor.author | Hasenburg, Annette | - |
dc.contributor.author | Denkert, Carsten | - |
dc.contributor.author | Schmidt, Marcus | - |
dc.date.accessioned | 2021-05-11T09:06:47Z | - |
dc.date.available | 2021-05-11T09:06:47Z | - |
dc.date.issued | 2020 | - |
dc.identifier.uri | https://openscience.ub.uni-mainz.de/handle/20.500.12030/5813 | - |
dc.description.abstract | PURPOSE Evaluating consecutive early breast cancer patients, we analyzed both the impact of EndoPredict® on clinical decisions as well as clinico-pathological factors influencing the decision to perform this gene expression test. METHODS Hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative early breast cancer patients treated between 2011 and 2016 were included in this study to investigate the role of EndoPredict® (EPclin) in the treatment of early breast cancer. A main study aim was to analyze the changes in therapy recommendations with and without EPclin. In addition, the impact of clinico-pathological parameters for the decision to perform EPclin was examined by Pearson's chi-squared test (χ2-test) and Fisher's exact test as well as univariate and multivariate logistic regressions. RESULTS In a cohort of 869 consecutive early HR-positive, HER-negative breast cancer patients, EPclin was utilized in 156 (18.0%) patients. EPclin led to changes in therapy recommendations in 33.3% (n = 52), with both therapy escalation in 19.2% (n = 30) and de-escalation in 14.1% (n = 22). The clinico-pathological factors influencing the use of EPclin were age (P < 0.001, odds ratio [OR] 0.498), tumor size (P = 0.011, OR 0.071), nodal status (P = 0.021, OR 1.674), histological grade (P = 0.043, OR 0.432), and Ki-67 (P < 0.001, OR 3.599). CONCLUSIONS EPclin led to a change in therapy recommendations in one third of the patients. Clinico-pathological parameters such as younger age, smaller tumor size, positive nodal status, intermediate histological grade and intermediate Ki-67 had a significant influence on the use of EndoPredict®. | en_GB |
dc.language.iso | eng | de |
dc.rights | CC BY | * |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | * |
dc.subject.ddc | 610 Medizin | de_DE |
dc.subject.ddc | 610 Medical sciences | en_GB |
dc.title | EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer | en_GB |
dc.type | Zeitschriftenaufsatz | de |
dc.identifier.doi | http://doi.org/10.25358/openscience-5804 | - |
jgu.type.dinitype | article | en_GB |
jgu.type.version | Published version | de |
jgu.type.resource | Text | de |
jgu.organisation.department | FB 04 Medizin | de |
jgu.organisation.number | 2700 | - |
jgu.organisation.name | Johannes Gutenberg-Universität Mainz | - |
jgu.rights.accessrights | openAccess | - |
jgu.journal.title | Breast cancer research and treatment | de |
jgu.journal.volume | 182 | de |
jgu.pages.start | 137 | de |
jgu.pages.end | 146 | de |
jgu.publisher.year | 2020 | - |
jgu.publisher.name | Springer Science + Business Media B.V. | de |
jgu.publisher.place | Dordrecht | de |
jgu.publisher.uri | https://doi.org/10.1007/s10549-020-05688-1 | de |
jgu.publisher.issn | 1573-7217 | de |
jgu.organisation.place | Mainz | - |
jgu.subject.ddccode | 610 | de |
jgu.publisher.doi | 10.1007/s10549-020-05688-1 | - |
jgu.organisation.ror | https://ror.org/023b0x485 | - |
Appears in collections: | JGU-Publikationen |
Files in This Item:
File | Description | Size | Format | ||
---|---|---|---|---|---|
almstedt_k.-endopredict®_i-20210421200952037.pdf | 729.63 kB | Adobe PDF | View/Open |